keyword
https://read.qxmd.com/read/37046717/combination-of-fdg-pet-ct-radiomics-and-clinical-parameters-for-outcome-prediction-in-patients-with-hodgkin-s-lymphoma
#21
JOURNAL ARTICLE
Claudia Ortega, Yael Eshet, Anca Prica, Reut Anconina, Sarah Johnson, Danny Constantini, Sareh Keshavarzi, Roshini Kulanthaivelu, Ur Metser, Patrick Veit-Haibach
PURPOSE: The aim of the study is to evaluate the prognostic value of a joint evaluation of PET and CT radiomics combined with standard clinical parameters in patients with HL. METHODS: Overall, 88 patients (42 female and 46 male) with a median age of 43.3 (range 21-85 years) were included. Textural analysis of the PET/CT images was performed using freely available software (LIFE X). 65 radiomic features (RF) were evaluated. Univariate and multivariate models were used to determine the value of clinical characteristics and FDG PET/CT radiomics in outcome prediction...
March 30, 2023: Cancers
https://read.qxmd.com/read/37023222/treatment-selection-and-survival-in-patients-with-gray-zone-lymphoma-a-comprehensive-population-based-analysis
#22
JOURNAL ARTICLE
Yazan Samhouri, Thejus T Jayakrishnan, Lynna Alnimer, Veli Bakalov, Rodney E Wegner, Cyrus Khan, Salman Fazal, John Lister
BACKGROUND AND OBJECTIVES: There are no treatment guidelines for gray-zone lymphoma (GZL), given the disease's rarity and being a relatively new entity. Our objective was to assess factors affecting treatment selection in GZL and its effect on survival, focusing on combined modality treatment (CMT) versus chemotherapy alone. PATIENTS AND METHODS: We identified 1047 patients with GZL treated with CMT or chemotherapy alone between 2004 and 2016 from the National Cancer Database (NCDB)...
April 4, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36898084/nivolumab-combined-with-brentuximab-vedotin-for-relapsed-refractory-mediastinal-gray-zone-lymphoma
#23
JOURNAL ARTICLE
Armando Santoro, Alison J Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J Savage
No abstract text is available yet for this article.
June 1, 2023: Blood
https://read.qxmd.com/read/36792059/risk-of-a-second-cancer-and-infection-in-patients-with-indolent-b-cell-lymphoma-exposed-to-first-line-bendamustine-plus-rituximab-a-retrospective-analysis-of-an-administrative-claims-database
#24
JOURNAL ARTICLE
Satoshi Dote, PhD Ryo Inose, Ryota Goto, Yuka Kobayashi, Yuichi Muraki
Bendamustine has a potent immunosuppressive effect because it causes T-cell lymphopenia, which might lead to a second primary malignancy (SPM) and would increase the risk of infection. Using the Medical Data Vision administrative claims database, we compared the cumulative incidence of SPM, infections within 6 months, and overall survival (OS) among untreated patients with indolent B-cell lymphomas (iBCL) who received rituximab-based chemotherapy between 2009 and 2020. Patients with grade 3b follicular lymphoma or a previous history of malignancy were excluded...
February 15, 2023: Hematological Oncology
https://read.qxmd.com/read/36634274/use-of-checkpoint-inhibitors-in-gray-zone-lymphoma
#25
JOURNAL ARTICLE
Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Fernando Ricardo Fernandes Paz, Naiana Castelo Branco Campos, João Paulo de Vasconcelos Leitão, Francisco Dário Rocha Filho, Ricardo Vale Albino Oliveira Filho, Romélia Pinheiro Gonçalves Lemes, Fernando Barroso Duarte
Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area lymphoma in August 2019, using a descriptive and cross-sectional analysis of the clinical history and disease evolution...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36575002/combined-use-of-pathological-and-genomic-alteration-analyses-for-the-diagnosis-of-gray-zone-lymphoma
#26
JOURNAL ARTICLE
Komei Nishimura, Kana Miyazaki, Kazutaka Suzuki, Kensuke Hachiya, Yasutaka Tono, Satoshi Tamaru, Hiroshi Imai, Hiroaki Miyoshi, Koichi Ohshima, Yoshinaga Okugawa, Isao Tawara, Motoko Yamaguchi
Histiocytic sarcoma (HS) is a rare malignancy showing morphologic and immunophenotypic features of histiocytes. HS has morphologic overlap with many other diseases, including various kinds of lymphomas. Gray zone lymphoma (GZL) is a rare B-cell lymphoma subtype characterized by overlapping features between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. The histologic overlap with other diverse diseases of HS and the pathological diversity of GZL make it difficult to render a diagnosis. A 44-year-old woman who was initially diagnosed with HS was diagnosed with GZL after reexamination, including a genetic alteration test...
2022: Journal of Clinical and Experimental Hematopathology: JCEH
https://read.qxmd.com/read/36274093/evolution-in-the-definition-and-diagnosis-of-the-hodgkin-lymphomas-and-related-entities
#27
REVIEW
Thomas A Tousseyn, Rebecca L King, Falko Fend, Andrew L Feldman, Pierre Brousset, Elaine S Jaffe
Hodgkin lymphoma was the first of the lymphomas to be recognized as a specific disease entity. However, recent studies have highlighted the heterogeneity of the diseases associated with this eponym warranting clarification and refinement of diagnostic terminology. While classic Hodgkin lymphoma (CHL) remains an essentially unchanged diagnostic entity in the 2022 International Consensus Classification of Mature Lymphoid Neoplasms (2022 ICC), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is now renamed nodular lymphocyte predominant B cell lymphoma (NLPBL) in recognition of the distinct pathologic, biologic, and clinical differences...
January 2023: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/36164028/hl-367-asct-for-treatment-resistant-mediastinal-gray-zone-lymphoma
#28
JOURNAL ARTICLE
Artem Oganesyan, Nerses Ghahramanyan, Lusine Harutyunyan, Gevorg Saghumyan, Vahagn Tamazyan, Karen Meliksetyan, Yervand Hakobyan
CONTEXT: Gray zone lymphoma (GZL) is a rare type of blood cancer with intermediate characteristics of diffuse large cell B lymphoma (DLCBL) and classical Hodgkin lymphoma (cHL). There is no universal approach to the management of GZL, and resistant cases often remain challenging. OBJECTIVE: To describe a potential treatment for mediastinal GZL (MGZL) resistant to standard chemotherapy regimens based on a clinical case report. PATIENTS OR OTHER PARTICIPANTS: A 40-year-old woman was admitted to the hospital with recent onset of generalized itchiness, weakness, fevers, and night sweats...
October 2022: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/36001451/targeted-mutational-profiling-reveals-clonal-relationships-in-metachronous-occurrence-of-classic-hodgkin-and-mediastinal-large-b-cell-lymphomas
#29
JOURNAL ARTICLE
Kunwar Singh, Lhara S Lezama, Jason Kurzer, Jean Oak, Liora M Schultz, Ann Walkush, Tse-Chang Cheng, Everett H Chen, William A May, Cheryl Chang, Michael P Link, Ranjana H Advani, Carlos J Suarez, Yasodha Natkunam
Classic Hodgkin lymphoma (CHL) patients may infrequently present with a prior or recurrent disease with discordant histology resembling non-Hodgkin lymphomas. These include primary mediastinal large B-cell lymphoma (PMBL), diffuse large B-cell lymphoma (DLBCL), or mediastinal gray-zone lymphoma (MGZL). Such patients are often refractory to standard therapy and their diagnosis is hampered by significant morphologic and immunophenotypic overlap and insufficient molecular data. Among 509 CHL patients seen at an academic medical center, 6 patients had a prior or subsequent diagnosis different from CHL...
August 25, 2022: American Journal of Surgical Pathology
https://read.qxmd.com/read/35979119/gray-zone-lymphoma-effectively-treated-with-cyclophosphamide-doxorubicin-vincristine-prednisolone-and-rituximab-chemotherapy-a-case-report
#30
Nobumasa Hojo, Makoto Nagasaki, Yasuha Mihara
BACKGROUND: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (BCLu-DLBCL/cHL), also referred to as gray zone lymphoma (GZL), is known to share features with cHL and DLBCL. However, GZL is often difficult to diagnose. There is no consensus regarding the optimal therapeutic regimen. Most reported cases of GZL have been in Caucasian and Hispanic individuals, and its incidence is lower in African-American and Asian populations, including the Japanese population...
June 16, 2022: World Journal of Clinical Cases
https://read.qxmd.com/read/35560252/long-term-outcomes-of-patients-with-conjunctival-extranodal-marginal-zone-lymphoma
#31
JOURNAL ARTICLE
Eduardo Edelman Saul, Juan Pablo Alderuccio, Isildinha M Reis, Wei Zhao, Sunil G Iyer, Gregor Rodriguez, Amrita Desai, Jennifer R Chapman, David T Tse, Arnold M Markoe, Derek M Isrow, Izidore S Lossos
Comprehensive information on clinical features and long-term outcomes of primary conjunctival extranodal marginal zone lymphoma (PCEMZL) is scarce. We present a large single-institution retrospective study of 72 patients. The median age was 64 years, and 63.9% were female. Stage I was present in 87.5%. Radiation therapy (RT) alone was the most common treatment (70.8%). Complete response (CR) was 87.5%, and 100% in RT-treated patients. With a median follow-up of 6.7 years, relapse/progression and death occurred in 19...
May 12, 2022: American Journal of Hematology
https://read.qxmd.com/read/34961399/discriminating-between-waldenstr%C3%A3-m-macroglobulinemia-and-marginal-zone-lymphoma-using-logistic-lasso-regression
#32
JOURNAL ARTICLE
Karima Amaador, Josephine M I Vos, Steven T Pals, Willem Kraan, Johan A Dobber, Monique C Minnema, Harry R Koene, Peter C de Bruin, Aiko H Zwinderman, Marie José Kersten
Discrimination between Waldenström macroglobulinemia (WM) and marginal zone lymphoma (MZL) of the bone marrow (BM) can be difficult due to overlap in clinical, histopathologic, and immunophenotypic characteristics. We determined which characteristics can aid in the differential diagnosis of 'gray zone' cases. We compared clinical, histopathologic, immunophenotypic, and molecular features of 222 WM and 65 MZL patients. LASSO regression was employed for variable selection. The most distinguishing clinical features of WM compared to MZL were the presence of the B-symptom weight loss and IgM paraprotein...
May 2022: Leukemia & Lymphoma
https://read.qxmd.com/read/34887712/radiomic-features-of-18-f-fdg-pet-in-hodgkin-lymphoma-are-predictive-of-outcomes
#33
JOURNAL ARTICLE
Yeye Zhou, Yuchun Zhu, Zhiqiang Chen, Jihui Li, Shibiao Sang, Shengming Deng
Purpose: In the present study, we aimed to investigate whether the radiomic features of baseline 18 F-FDG PET can predict the prognosis of Hodgkin lymphoma (HL). Methods: A total 65 HL patients (training cohort: n  = 49; validation cohort: n  = 16) were retrospectively enrolled in the present study. A total of 47 radiomic features were extracted from pretreatment PET images. The least absolute shrinkage and selection operator (LASSO) regression was used to select the most useful prognostic features in the training cohort...
2021: Contrast Media & Molecular Imaging
https://read.qxmd.com/read/34877288/clinical-observation-of-pediatric-type-follicular-lymphomas-in-adult-two-case-reports
#34
Yao Liu, Hui Xing, Yue-Ping Liu
BACKGROUND: Pediatric-type follicular lymphoma (PTFL) is a unique pathological type in the 4th edition of hematopoiesis and lymphoid tissue tumor classification revised by World Health Organization. It is unique in clinical practice and seldom seen in adult. PTFL mainly occurs in the head and neck lymph nodes. Most of the cases are short of fever, night sweat, weight loss, and other B symptoms which substitute for lymphadenopathy as the main symptom. PTFL can be disposed of surgical resection and it can achieve long-term tumor-free survival, and it has an excellent outcome...
November 6, 2021: World Journal of Clinical Cases
https://read.qxmd.com/read/34856873/comparative-analysis-of-international-prognostic-indices-in-gray-zone-lymphoma
#35
JOURNAL ARTICLE
Hanno M Witte, Hartmut Merz, Heinz-Wolfram Bernd, Arthur Bauer, Veronica Bernard, Alfred C Feller, Niklas Gebauer
Gray-zone lymphoma (GZL) reflects an aggressive B-cell neoplasm with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). The International Prognostic Index (IPI) and its derivatives (R-IPI, NCCN-IPI, and the Hasenclever IPS) have been established for DLBCL or cHL while the most suitable scoring system for GZL remains undetermined. In an exploratory multi-centric cohort of GZL ( n  = 61), we performed a comparative analysis of prognostic indices with regard to model fit and mutual concordance...
April 2022: Leukemia & Lymphoma
https://read.qxmd.com/read/34701143/disease-outcomes-following-low-dose-radiotherapy-vs-moderate-dose-radiotherapy-for-orbital-low-grade-non-hodgkin-lymphoma
#36
JOURNAL ARTICLE
C M Wright, J Baron, D Y Lee, M Carpenter, E J Anstadt, C A Briceño, E A Chong, A Maity, J P Plastaras, I Paydar
PURPOSE/OBJECTIVE(S): Orbital low grade non-Hodgkin Lymphomas (LGNHLs) are a common tumor of the ocular adnexa. Courses of low-dose radiotherapy (LDRT), previously defined as 2 Gray (Gy) x 2 fractions, have resulted in excellent short-term outcomes for orbital LGNHLs. Recent data, however, suggests that higher doses are associated with improvements in response rates and progression free survival. RT is a proven treatment modality for this entity, but no prior data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose > 4 Gy)...
November 1, 2021: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/34398178/how-i-diagnose-primary-mediastinal-thymic-large-b-cell-lymphoma
#37
REVIEW
Sarah L Ondrejka, German Ott
OBJECTIVES: Primary mediastinal (thymic) large B-cell lymphoma (PMBL) is an uncommon large B-cell neoplasm recognized by the World Health Organization as a distinct entity on the basis of its unique clinical features, histogenesis, phenotype, and pathogenetic mechanisms. The diagnosis of PMBL can be challenging because of features that may overlap with other (Hodgkin and non-Hodgkin) lymphoma types. This review describes our approach to the diagnosis of PMBL. METHODS: Two cases are presented to illustrate how we diagnose PMBL and separate PMBL from related histologic and biological mimickers, such as Hodgkin lymphoma and gray zone lymphoma...
September 8, 2021: American Journal of Clinical Pathology
https://read.qxmd.com/read/34304771/the-hematological-differential-diagnosis-of-mediastinal-masses
#38
REVIEW
Ahmed Aljudi, Elizabeth Weinzierl, Mohamed Elkhalifa, Sunita Park
Mediastinal masses commonly present in children and may pose diagnostic challenges, particularly with limited sampling. This article aids the pathologist by reviewing the hematologic differential diagnosis of a pediatric mediastinal mass, along with ancillary testing useful for rendering the correct diagnosis. A review of the more common lymphomas is presented, including classic Hodgkin lymphoma, T-lymphoblastic leukemia/lymphoma, and primary mediastinal (thymic) large B-cell lymphoma, along with brief mentions of less common entities such as gray zone lymphoma and thymoma as well as non-neoplastic conditions such as benign cysts and infections...
September 2021: Clinics in Laboratory Medicine
https://read.qxmd.com/read/34257590/transition-between-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma-our-histopathological-and-clinical-experience-with-patients-with-intermediate-lymphoma
#39
JOURNAL ARTICLE
Zsófia Simon, Bálint Virga, László Pinczés, Gábor Méhes, Zsófia Miltényi, Sándor Barna, Roxana Szabó, Árpád Illés
Even though information about the pathophysiology and clinical features of grey-zone lymphoma, an entity intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma, is growing, there are still a number of unanswered questions. The disease has no easily reproducible diagnostic criteria, which makes identification challenging. Uncommon, mixed histological picture and unusual clinical presentation should raise suspicion for grey-zone lymphoma. In this retrospective analysis we present 9 gray zone lymphoma patients, who were diagnosed in our institute between 2008 and 2018...
2021: Pathology Oncology Research: POR
https://read.qxmd.com/read/34176939/texture-indices-of-18f-fdg-pet-ct-for-differentiating-squamous-cell-carcinoma-and-non-hodgkin-s-lymphoma-of-the-oropharynx
#40
JOURNAL ARTICLE
Katsuya Mitamura, Takashi Norikane, Yuka Yamamoto, Ayumi Ihara-Nishishita, Takuya Kobata, Kengo Fujimoto, Yasukage Takami, Nobuyuki Kudomi, Hiroshi Hoshikawa, Yoshihiro Nishiyama
We assessed the role of 18F-FDG PET/CT texture indices for the differentiation of squamous cell carcinoma (SCC) and non-Hodgkin's lymphoma (NHL) in the oropharynx. 18F-FDG PET/CT data for 27 patients with SCC and 25 patients with NHL in the oropharynx were investigated. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and six texture indices (homogeneity, entropy, short-run emphasis, long-run emphasis, low gray-level zone emphasis [LGZE], and high graylevel zone emphasis [HGZE]) were derived from PET images...
June 2021: Acta Medica Okayama
keyword
keyword
113475
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.